MCID: ACT010
MIFTS: 52

Acth-Secreting Pituitary Adenoma

Categories: Bone diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Acth-Secreting Pituitary Adenoma

MalaCards integrated aliases for Acth-Secreting Pituitary Adenoma:

Name: Acth-Secreting Pituitary Adenoma 12 53 44 15 73
Cushing Disease 53 25
Pituitary-Dependant Hypercortisolism Disorder 25
Pituitary-Dependent Cushing's Disease 73
Pituitary Corticotroph Micro-Adenoma 53
Pituitary Dependent Cushing Syndrome 53
Pituitary-Dependent Cushing Syndrome 53
Pituitary-Dependant Cushing Syndrome 25
Pituitary-Dependant Hypercortisolism 25
Pituitary-Dependent Cushings Disease 55
Adenoma, Pituitary, Acth-Secreting 40
Pituitary Adenoma, Acth-Secreting 13
Acth-Producing Pituitary Adenoma 12
Pituitary Acth-Secreting Adenoma 13
Corticotroph Pituitary Adenoma 53
Pituitary Acth Hypersecretion 25
Adrenal Gland Hyperfunction 73
Pituitary Cushing Syndrome 25
Corticotroph Adenoma 12
Cushing's Disease 53
Cushing Syndrome 73
Corticotropinoma 12
Hypercortisolism 25

Classifications:



External Ids:

Disease Ontology 12 DOID:7004
MeSH 44 D049913
NCIt 50 C7462
SNOMED-CT 68 21109002

Summaries for Acth-Secreting Pituitary Adenoma

NIH Rare Diseases : 53 ACTH-secreting pituitary adenoma is a condition characterized by elevated levels of a hormone called cortisol secreted by a tumor in the pituitary gland. It is part of a group of diseases that cause Cushing�??s syndrome, characterized by signs and symptoms that may include weight gain around the trunk and in the face, stretch marks, easy bruising, a hump on the upper back, muscle weakness, tiredness, thin bones that are prone to fracture (osteoporosis), mood disorders and memory problems, as well as an increased risk of infections, high blood pressure and diabetes. Women may have irregular menses and a lot of hair in the body (hirsutism). It  occurs when a benign pituitary tumor (adenoma) or pituitary hyperplasia causes the adrenal glands to produce large amounts of cortisol.  Some cases are caused by somatic mutations in the AIP and the GNAS genes. Rarely, an ACTH-secreting pituitary adenoma can be inherited, either as an isolated condition or as part of a genetic syndrome (such as multiple endocrine neoplasia type 1 (MEN1) and familial isolated pituitary adenoma), but most cases are sporadic. Treatment generally involves surgery to remove the tumor and medications to decrease cortisol levels.

MalaCards based summary : Acth-Secreting Pituitary Adenoma, also known as cushing disease, is related to pituitary-dependent cushing's disease and primary pigmented nodular adrenocortical disease, and has symptoms including cushingoid facies An important gene associated with Acth-Secreting Pituitary Adenoma is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and Prolactin Signaling Pathway. The drugs Pasireotide and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and adrenal gland, and related phenotypes are Increased cell death HMECs cells and endocrine/exocrine gland

Disease Ontology : 12 A functioning pituitary adenoma that characterized by excess cortisol a primary cause of Cushing's syndrome.

Wikipedia : 76 Cushing''s syndrome is a collection of signs and symptoms due to prolonged exposure to cortisol. Signs... more...

Related Diseases for Acth-Secreting Pituitary Adenoma

Diseases in the Acth-Secreting Pituitary Adenoma family:

Pituitary Adenoma 4, Acth-Secreting

Diseases related to Acth-Secreting Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 pituitary-dependent cushing's disease 32.2 CRH POMC PRL
2 primary pigmented nodular adrenocortical disease 31.5 NR3C1 POMC
3 adenoma 31.0 POMC PRL USP8
4 pituitary tumors 30.2 POMC PRL
5 empty sella syndrome 30.1 POMC PRL
6 cortisone reductase deficiency 30.0 NR3C1 POMC
7 conn's syndrome 30.0 CRH NR3C1 POMC PRL
8 adrenal adenoma 29.9 CRH POMC
9 pituitary carcinoma 29.8 CRH POMC PRL
10 hyperandrogenism 29.8 POMC PRL
11 hypoadrenalism 29.8 CRH POMC
12 withdrawal disorder 29.8 CRH POMC
13 nelson syndrome 29.8 CRH NR3C1 POMC PRL
14 ectopic cushing syndrome 29.8 CRH POMC
15 hypokalemia 29.8 NR3C1 POMC
16 functioning pituitary adenoma 29.7 POMC PRL
17 hyperprolactinemia 29.6 POMC PRL
18 pituitary apoplexy 29.6 POMC PRL
19 amenorrhea 29.5 CRH POMC PRL
20 anorexia nervosa 29.3 CRH POMC PRL
21 bipolar disorder 29.3 CRH NR3C1 PRL
22 pituitary adenoma 4, acth-secreting 11.6
23 mccune-albright syndrome 11.4
24 pituitary adenoma 1, multiple types 11.2
25 acth-independent macronodular adrenal hyperplasia 11.1
26 malignant acth producing neoplasm of pituitary gland 11.1
27 lipodystrophy, familial partial, type 2 10.9
28 familial partial lipodystrophy 10.9
29 pituitary adenoma 10.8
30 ovarian serous adenofibroma 10.2 NR3C1 POMC
31 hyperaldosteronism, familial, type i 10.1 NR3C1 POMC
32 allergic urticaria 10.1 CRH NR3C1
33 corticosteroid-binding globulin deficiency 10.1 NR3C1 POMC
34 osteoporosis 10.1
35 leukemia 10.1
36 cryptococcal meningitis 10.1
37 teratoma 10.1
38 ovarian germ cell teratoma 10.1
39 meningitis 10.1
40 familial glucocorticoid deficiency 10.1
41 gangliocytoma 10.1 CRH POMC
42 acth deficiency, isolated 10.1 CRH POMC
43 acromegaly 10.1
44 fasting hypoglycemia 10.1 CRH POMC
45 adrenal cortical hypofunction 10.1 CRH POMC
46 persistent fetal circulation syndrome 10.1 CRH POMC
47 pituitary infarct 10.1 POMC PRL
48 chiasmal syndrome 10.1 POMC PRL
49 adenohypophysitis 10.1 POMC PRL
50 sella turcica neoplasm 10.1 POMC PRL

Graphical network of the top 20 diseases related to Acth-Secreting Pituitary Adenoma:



Diseases related to Acth-Secreting Pituitary Adenoma

Symptoms & Phenotypes for Acth-Secreting Pituitary Adenoma

UMLS symptoms related to Acth-Secreting Pituitary Adenoma:


cushingoid facies

GenomeRNAi Phenotypes related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 8.92 IGFBP6 NR3C1 PRKCD USP8

MGI Mouse Phenotypes related to Acth-Secreting Pituitary Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.35 CRH NR3C1 POMC PRKCD PRL
2 liver/biliary system MP:0005370 9.1 CRH NR3C1 POMC PRKCD PRL USP8

Drugs & Therapeutics for Acth-Secreting Pituitary Adenoma

Drugs for Acth-Secreting Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pasireotide Approved Phase 4,Phase 3,Phase 2 396091-73-9 9941444
2
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2 51110-01-1, 38916-34-6 53481605
3
Metformin Approved Phase 4 657-24-9 14219 4091
4
Zinc Approved, Investigational Phase 4 7440-66-6
5
Liraglutide Approved Phase 4 204656-20-2 44147092
6
Lactitol Investigational Phase 4 585-86-4 3871
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
9 Hormones Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
10 Insulin, Globin Zinc Phase 4
11 insulin Phase 4
12
protease inhibitors Phase 4
13 Sitagliptin Phosphate Phase 4
14 Incretins Phase 4
15 Hypoglycemic Agents Phase 4,Phase 2
16 Dipeptidyl-Peptidase IV Inhibitors Phase 4
17 HIV Protease Inhibitors Phase 4
18
Mifepristone Approved, Investigational Phase 3,Phase 2,Not Applicable 84371-65-3 55245
19
Racepinephrine Approved Phase 3,Phase 2,Not Applicable 329-65-7 838
20
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Not Applicable 51-43-4 5816
21
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
22
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
23
Cabergoline Approved Phase 3,Phase 2 81409-90-7 54746
24
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
25 Orange Approved Phase 3
26
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
27
Ketoconazole Approved, Investigational Phase 3 65277-42-1 3823 47576
28 Contraceptive Agents Phase 3,Phase 2,Not Applicable
29 Contraceptives, Oral Phase 3,Phase 2,Not Applicable
30 Contraceptives, Postcoital Phase 3,Phase 2,Not Applicable
31 Luteolytic Agents Phase 3,Phase 2,Not Applicable
32 Epinephryl borate Phase 3,Phase 2,Not Applicable
33 glucocorticoids Phase 3,Phase 2,Not Applicable
34 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
35 Cortisol succinate Phase 3,Phase 2
36 beta-endorphin Phase 3,Phase 2
37 Pharmaceutical Solutions Phase 3
38 Melanocyte-Stimulating Hormones Phase 3,Phase 2
39 Adrenocorticotropic Hormone Phase 3,Phase 2,Early Phase 1
40 Dopamine agonists Phase 3,Phase 2
41 Antiparkinson Agents Phase 3,Phase 2
42 Dopamine Agents Phase 3,Phase 2
43 Neurotransmitter Agents Phase 3,Phase 2
44 Radiopharmaceuticals Phase 3
45 Antineoplastic Agents, Hormonal Phase 3,Phase 2
46 Gastrointestinal Agents Phase 3,Phase 2
47 Edotreotide Phase 3
48
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
49
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
50
Nicotinamide Approved, Investigational Phase 2 98-92-0 936

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
2 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
4 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
5 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
6 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
7 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
8 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
9 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
10 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
11 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
12 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
13 A Study of the Efficacy and Safety of Relacorilant Recruiting NCT03697109 Phase 3 Relacorilant
14 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699;LCI699 matching placebo
15 Open-label Treatment in Cushing's Syndrome Not yet recruiting NCT03621280 Phase 3 Levoketoconazole
16 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
17 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
18 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
19 Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment Unknown status NCT02713776 Phase 2 Pasireotide;Placebo
20 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
21 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
22 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
23 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
24 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
25 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
26 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
27 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
28 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
29 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
30 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
31 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
32 Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease Not yet recruiting NCT03708900 Phase 2 LCI699
33 Treatment of Cushing's Disease With R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
34 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
35 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
36 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2 Pasireotide
37 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2 Mifepristone
38 Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Terminated NCT00813592 Phase 2 SOM230B
39 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
40 SOM230 Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
41 Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease Unknown status NCT02603653 Not Applicable
42 Study of Depression, Peptides, and Steroids in Cushing's Syndrome Unknown status NCT00004334
43 Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia Unknown status NCT02810496 Not Applicable
44 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332 Not Applicable
45 Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B. Unknown status NCT02651844 Not Applicable Mifepristone
46 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
47 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
48 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
49 Effects of Hormone Stimulation on Brain Scans for Cushing s Disease Completed NCT01459237 Early Phase 1 Acthrel
50 Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Completed NCT00001453

Search NIH Clinical Center for Acth-Secreting Pituitary Adenoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: acth-secreting pituitary adenoma

Genetic Tests for Acth-Secreting Pituitary Adenoma

Anatomical Context for Acth-Secreting Pituitary Adenoma

MalaCards organs/tissues related to Acth-Secreting Pituitary Adenoma:

41
Pituitary, Bone, Adrenal Gland, Skin, Lung, Liver, Thyroid

Publications for Acth-Secreting Pituitary Adenoma

Articles related to Acth-Secreting Pituitary Adenoma:

(show top 50) (show all 200)
# Title Authors Year
1
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. ( 29143885 )
2018
2
Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs. ( 29864631 )
2018
3
Endocrine Remission After Pituitary Stereotactic Radiosurgery: Differences in Rates of Response for Matched Cohorts of Cushing Disease and Acromegaly Patients. ( 29678528 )
2018
4
Integration of Proteomics and Metabolomics Revealed Metabolite-Protein Networks in ACTH-Secreting Pituitary Adenoma. ( 30532734 )
2018
5
The Value of Perioperative Levels of ACTH, DHEA, and DHEA-S and Tumor Size in Predicting Recurrence of Cushing Disease. ( 29244084 )
2018
6
Variability of Late-Night Salivary Cortisol in Cushing Disease: A Prospective Study. ( 29329418 )
2018
7
CyberKnife Radiosurgery in the Multimodal Management of Patients with Cushing Disease. ( 29355797 )
2018
8
Management of Cerebral Venous and Sinus Thrombosis Following Transsphenoidal Surgery for Cushing Disease During Early Postoperative Period: Uncommon Neurosurgical Complication. ( 29499593 )
2018
9
Technique of Whole-Sellar Stereotactic Radiosurgery for Cushing Disease: Results from a Multicenter, International Cohort Study. ( 29783006 )
2018
10
New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A. ( 29881371 )
2018
11
Children with MEN1 gene mutations may present first (and at a young age) with Cushing disease. ( 29927501 )
2018
12
Outcome of Transsphenoidal Surgery for Cushing Disease: A Single-Center Experience over 20 Years. ( 30031194 )
2018
13
PATHOGENESIS OF CUSHING DISEASE: AN UPDATE ON THE GENETICS OF CORTICOTROPINOMAS. ( 30084690 )
2018
14
Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease. ( 30147673 )
2018
15
Hypothalamic Vasopressin-producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease. ( 30379651 )
2018
16
Neurosurgical treatment of Cushing disease in pediatric patients: case series and review of literature. ( 30488233 )
2018
17
Tumor-directed therapeutic targets in Cushing disease. ( 30535260 )
2018
18
Long-term outcomes of tissue-based ACTH-antibody assay-guided transsphenoidal resection of pituitary adenomas in Cushing disease. ( 29027854 )
2018
19
Cryptococcal meningitis after transnasal transsphenoidal pituitary microsurgery of ACTH-secreting pituitary adenoma: A case report. ( 28700464 )
2017
20
A rare association: Cushing disease and central serous chorioretinopathy. ( 28457311 )
2017
21
Cushing Disease in a patient with Multiple Endocrine Neoplasia type 2B. ( 28435794 )
2017
22
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. ( 27448294 )
2017
23
The Molecular Pathology of Cushing Disease: Are We Nearly There? ( 29264473 )
2017
24
Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome. ( 27395418 )
2017
25
Endoscopic Endonasal Surgery for Remission of Cushing Disease Caused by Ectopic Intracavernous Macroadenoma: Case Report and Literature Review. ( 28003168 )
2017
26
Rapid Deterioration of Latent HBV Hepatitis during Cushing Disease and Posttraumatic Stress Disorder after Earthquake. ( 28183144 )
2017
27
Normalized Early Postoperative Cortisol and ACTH Values Predict Nonremission After Surgery for Cushing Disease. ( 28323961 )
2017
28
LONG-TERM OUTCOME OF THE DIFFERENT TREATMENT ALTERNATIVES FOR RECURRENT AND PERSISTENT CUSHING DISEASE. ( 28332874 )
2017
29
Diabetes in Cushing Disease. ( 28364356 )
2017
30
Pediatric Cushing disease: disparities in disease severity and outcomes in the Hispanic and African-American populations. ( 28422946 )
2017
31
Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease. ( 28505327 )
2017
32
Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations. ( 28529722 )
2017
33
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. ( 28614003 )
2017
34
Outcomes of Primary Transsphenoidal Surgery in Cushing Disease: Experience of a Tertiary Center. ( 28711536 )
2017
35
Otolaryngic manifestations of Cushing disease. ( 28846797 )
2017
36
Cushing Disease: Are We Making Progress? ( 28899077 )
2017
37
Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study. ( 28938462 )
2017
38
Pituitary gland: Gamma Knife for Cushing disease - time for a reappraisal? ( 29019347 )
2017
39
A rare case of multiple pituitary adenomas in an adolescent Cushing disease presenting as a vertebral compression fracture. ( 29025207 )
2017
40
Correction: Lycopene and Beta-Carotene Induce Growth Inhibition and Proapoptotic Effects on ACTH-Secreting Pituitary Adenoma Cells. ( 26848958 )
2016
41
Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma. ( 28005257 )
2016
42
Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis. ( 27690016 )
2016
43
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells. ( 26522132 )
2016
44
Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms. ( 27517036 )
2016
45
Kidney Stones as an Underrecognized Clinical Sign in Pediatric Cushing Disease. ( 26703870 )
2016
46
Outcome of Transsphenoidal Surgery for Cushing Disease: A Single-Center Experience Over 32 Years. ( 26348007 )
2016
47
Performance of the 4-mg intravenous dexamethasone suppression test in differentiating Cushing disease from pseudo-Cushing syndrome. ( 26656734 )
2016
48
Utility of Exposure-Response Analysis in Regulatory Decision on the Selection of Starting Dose of Pasireotide for Cushing Disease. ( 26686944 )
2016
49
PREDICTORS OF BIOCHEMICAL REMISSION AND RECURRENCE AFTER SURGICAL AND RADIATION TREATMENTS OF CUSHING DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. ( 26789343 )
2016
50
IDENTIFICATION OF POTENTIAL MARKERS FOR CUSHING DISEASE. ( 26789346 )
2016

Variations for Acth-Secreting Pituitary Adenoma

Cosmic variations for Acth-Secreting Pituitary Adenoma:

9 (show all 35)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM4997287 USP8 pituitary,NS,adenoma,ACTH c.2152T>C p.S718P 15:50490443-50490443 52
2 COSM1749198 USP8 pituitary,NS,adenoma,ACTH c.2159C>G p.P720R 15:50490450-50490450 52
3 COSM416905 USP8 pituitary,NS,adenoma,ACTH c.2159C>A p.P720Q 15:50490450-50490450 52
4 COSM6995415 USP8 pituitary,NS,adenoma,ACTH c.2147C>A p.S716Y 15:50490438-50490438 52
5 COSM5967228 USP8 pituitary,NS,adenoma,ACTH c.2155T>C p.S719P 15:50490446-50490446 52
6 COSM3501986 USP8 pituitary,NS,adenoma,ACTH c.2147C>T p.S716F 15:50490438-50490438 52
7 COSM5967229 USP8 pituitary,NS,adenoma,ACTH c.2153C>T p.S718F 15:50490444-50490444 52
8 COSM5991542 STAG2 pituitary,NS,adenoma,ACTH c.1363G>C p.G455R 23:124057924-124057924 52
9 COSM28544 PIK3CA pituitary,NS,adenoma,ACTH c.3026G>A p.G1009E 3:179234183-179234183 52
10 COSM303944 PIK3CA pituitary,NS,adenoma,ACTH c.2984C>A p.A995D 3:179234141-179234141 52
11 COSM22589 MEN1 pituitary,NS,adenoma,ACTH c.1230C>A p.F410L 11:64805154-64805154 52
12 COSM482 HRAS pituitary,NS,adenoma,ACTH c.34G>C p.G12R 11:534289-534289 52
13 COSM27887 GNAS pituitary,NS,adenoma,ACTH c.601C>T p.R201C 20:58909365-58909365 52
14 COSM27896 GNAS pituitary,NS,adenoma,ACTH c.680A>G p.Q227R 20:58909541-58909541 52
15 COSM5991541 BCOR pituitary,NS,adenoma,ACTH c.283G>A p.G95R 23:40075063-40075063 52
16 COSM10654 TP53 skin,face,other,hyperplasia c.637C>T p.R213* 17:7674894-7674894 4
17 COSM10995 TP53 skin,face,other,hyperplasia c.580C>T p.L194F 17:7674951-7674951 4
18 COSM43939 TP53 skin,face,other,hyperplasia c.632C>T p.T211I 17:7674899-7674899 4
19 COSM45444 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.587G>T p.R196L 17:7674944-7674944 4
20 COSM43555 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.736A>G p.M246V 17:7674227-7674227 4
21 COSM225014 RB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1960G>A p.V654M 13:48456349-48456349 4
22 COSM4167506 PRKACA adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.617T>G p.L206R 19:14097604-14097604 4
23 COSM27899 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.601C>A p.R201S 20:58909365-58909365 4
24 COSM27895 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.602G>A p.R201H 20:58909366-58909366 4
25 COSM4962873 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.679C>G p.Q227E 20:58909540-58909540 4
26 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.133T>C p.S45P 3:41224645-41224645 4
27 COSM5689 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.134C>G p.S45C 3:41224646-41224646 4
28 COSM5678 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.107A>C p.H36P 3:41224619-41224619 4
29 COSM5667 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.134C>T p.S45F 3:41224646-41224646 4
30 COSM5686 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.100G>A p.G34R 3:41224612-41224612 4
31 COSM5679 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.110C>G p.S37C 3:41224622-41224622 4
32 COSM17661 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.130C>G p.P44A 3:41224642-41224642 4
33 COSM5988492 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.101G>C p.G34A 3:41224613-41224613 4
34 COSM5681 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.95A>G p.D32G 3:41224607-41224607 4
35 COSM476 BRAF adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1799T>A p.V600E 7:140753336-140753336 4

Expression for Acth-Secreting Pituitary Adenoma

Search GEO for disease gene expression data for Acth-Secreting Pituitary Adenoma.

Pathways for Acth-Secreting Pituitary Adenoma

Pathways related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.03 CRH IGFBP6 PRKCD
2
Show member pathways
11.95 NR3C1 PRKCD PRL
3
Show member pathways
11.84 CRH POMC USP8
4 11.3 CRH POMC PRKCD
5 10.71 NR3C1 POMC PRL
6 9.8 CRH POMC

GO Terms for Acth-Secreting Pituitary Adenoma

Biological processes related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.55 CRH IGFBP6 NR3C1 POMC PRKCD
2 parturition GO:0007567 8.96 CRH PRL
3 cellular response to dexamethasone stimulus GO:0071549 8.8 CRH NR3C1 USP8

Molecular functions related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.13 CRH IGFBP6 POMC
2 hormone activity GO:0005179 8.8 CRH POMC PRL

Sources for Acth-Secreting Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....